{"entity":{"id":"nsclc-3","kind":"trial","name":"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)","aka":[],"tldr":"A phase 3 trial testing TGRX-326 in non-small-cell lung cancer, active and no longer recruiting.","summary":"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT06082635, led by Shenzhen TargetRx with Sun Yat-Sen University Cancer Center, and active but no longer recruiting on the registry. Official title: A Multi-centered, Randomised, Open-label Phase III Study to Evaluate the Efficacy and Safety of TGRX-326 Comparing With Crizotinib in Patients of Advanced ALK-positive or Metastatic Non-Small Cell Lung Cancer. Planned enrolment is 321 participants (actual). The study started in 2023-12-14 and primary completion is expected in 2026-04-30. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06082635","url":"https://clinicaltrials.gov/study/NCT06082635"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","alk-positive-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["tgrx-326"],"companies":["shenzhen-targetrx"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06082635","phase":"3","setting":"A Multi-centered, Randomized, Open-label Phase III Study to Evaluate the Efficacy and Safety of TGRX-326 Comparing With Crizotinib in Patients of Advanced ALK-positive or Metastatic Non-Small Cell Lung Cancer","sponsor":"Shenzhen TargetRx","participation":[{"nct":"NCT06082635","source":"https://clinicaltrials.gov/study/NCT06082635","fetchedAt":"2026-10-07T16:54:11.803Z","studySha256":"70862812743da3d8872d71b468326ccf1504d34b0eacead69c377f8a51dd5cf6","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-05-18","leadSponsor":"Shenzhen TargetRx Co., Ltd.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":321,"enrolmentType":"ACTUAL","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2023-12-14","startedType":"actual","enrolled":321,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nsclc-3/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"tgrx-326","kind":"drug","name":"TGRX-326","route":"/drugs/tgrx-326/"}],"company":[{"id":"shenzhen-targetrx","kind":"company","name":"Shenzhen TargetRx","route":"/companies/shenzhen-targetrx/"}]}}